BOSTON SCIENTIFIC CORP (BSX.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:BSX - US1011371077 - Common Stock
BSX.DE Key Statistics, Chart & Performance
The current stock price of BSX.DE is 80.8 EUR. In the past month the price decreased by -7.76%. In the past year, price decreased by -13.58%.
BSX.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 17.78 | 109.21B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 19.31 | 52.07B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 16.65 | 23.73B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 16.52 | 23.54B | ||
| BIM.PA | BIOMERIEUX | 29.4 | 13.43B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 149.15 | 4.49B | ||
| DIA.MI | DIASORIN SPA | 21.67 | 4.01B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 26.83 | 3.86B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 11.12 | 1.35B | ||
| ELN.MI | EL.EN. SPA | 22.41 | 1.15B | ||
| DRW8.DE | DRAEGERWERK AG | 9.15 | 1.11B | ||
| EUZ.DE | ECKERT & ZIEGLER SE | 24.05 | 993.14M |
Related stock screener links
About BSX.DE
Company Profile
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Company Info
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS US
Employees: 53000
Phone: 15086834000
BOSTON SCIENTIFIC CORP / BSX.DE FAQ
What does BOSTON SCIENTIFIC CORP do?
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
What is the current price of BSX stock?
The current stock price of BSX.DE is 80.8 EUR. The price decreased by -0.74% in the last trading session.
Does BOSTON SCIENTIFIC CORP pay dividends?
BSX.DE does not pay a dividend.
What is the ChartMill rating of BOSTON SCIENTIFIC CORP stock?
BSX.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the employee count for BSX stock?
BOSTON SCIENTIFIC CORP (BSX.DE) currently has 53000 employees.
BSX.DE Technical Analysis
BSX.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE. BSX.DE has only an average score on both its financial health and profitability.
BSX.DE Financial Highlights
Over the last trailing twelve months BSX.DE reported a non-GAAP Earnings per Share(EPS) of 2.51. The EPS increased by 25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.42% | ||
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| Debt/Equity | 0.48 |
BSX.DE Forecast & Estimates
40 analysts have analysed BSX.DE and the average price target is 109.09 EUR. This implies a price increase of 35.01% is expected in the next year compared to the current price of 80.8.
For the next year, analysts expect an EPS growth of 22.13% and a revenue growth 20.9% for BSX.DE